Find raw sequence data, variant tables, expression matrices, and experimental metadata.
Press Enter ↵ to solve
Fuel Your Discoveries
"Just like a single cell, the character of our lives is determined not by our genes but by our responses to the environmental signals that propel life."
- Bruce H. Lipton
Quick Explanation
Copied
Design a GAS5 CRISPR-KO study in PDX tumors by structuring: (1) target/guide design + controls, (2) editing/validation, (3) in vivo PDX randomization + endpoints, and (4) mechanistic readouts—while pre-registering statistics and blinding where possible.
GAS5 CRISPR-KO in PDX: experiment design blueprint
April 28, 2026 • Skeptical, evidence-grounded, controls-first
0) Reality check (what we can and cannot assume)
“GAS5 CRISPR KO” here means: knocking out or functionally abolishing GAS5 gene function in tumor cells used to establish/propagate the PDX model. The exact biological mechanism (loss-of-transcript vs locus deletion vs disruption of regulatory elements) must be defined in your construct and validated empirically.
PDX outcomes can vary by patient tumor biology, engraftment efficiency, passage number, and mouse cohort effects; robust randomization and replication across PDX lines are important for interpretability in translational settings .
CRISPR KO concept relies on guide RNA directing Cas9 cleavage at a genomic target, producing indels that can disrupt function; your guide design and validation decide whether it is truly a functional KO .
If you want GAS5-specific effect sizes or prior findings to set sample size, you should pull full-text results from your exact tumor context; I can help with that if you provide the tumor type (e.g., lung adenocarcinoma), PDX subtype, and whether you intend in vitro editing then engraft vs in vivo delivery.
1) Overall experimental logic (controls-first)
Minimal control set (strongly recommended):
Vehicle / no-edit control (to capture delivery artifacts).
Non-targeting guide control (to capture guide-delivery + selection effects).
Multiple independent guides per GAS5 to reduce the probability that an observed phenotype is due to an off-target or guide-specific artifact.
Orthogonal validation (sequence confirmation of edits + GAS5 RNA loss, if measurable in your system).
2) Timeline & decision gates
Decision gates (explicit go/no-go):
Edit gate: confirm on-target edits at expected locus; reject batches where editing is low or heterogeneous.
Expression gate: verify GAS5 loss at the RNA level if feasible (or verify locus disruption proxy if not).
Engraft gate: require comparable engraftment/starting tumor burden across groups (or model it statistically).
Batch gate: keep mouse cohorts and processing dates balanced across experimental groups.
3) Editing strategy specifics (what you should pre-register)
CRISPR KO strategy (skeptical checklist):
Guide selection: specify genomic coordinates and off-target assessment method; use multiple independent guides per KO hypothesis .
Edit type: decide whether you target an early exon to maximize loss-of-function vs using a strategy that deletes the locus; record which validation outputs map to functional KO.
Validation: report (i) indel rates (and distribution), (ii) sequence confirmation in a sample fraction, and (iii) GAS5 RNA loss (if measurable).
Blind spots to watch: clonal drift, selection against certain edit outcomes during engraftment, and batch effects in delivery/processing—these can create apparent phenotypes independent of GAS5 biology.
4) PDX experimental endpoints (choose primary before results)
Examples of what to predefine (do not wait for outcomes):
Primary: tumor growth rate, time-to-endpoint, or final tumor volume—pick one to avoid multiplicity.
Rescue/orthogonal approach: if feasible in your system, perform an orthogonal perturbation strategy to triangulate causality (e.g., independent genetic targeting strategy).
Off-target audit: if a phenotype is observed, investigate whether predicted off-target loci show enrichment/changes.
This is critical in CRISPR studies where cleavage depends on guide RNA targeting, so off-target/guide-specific artifacts are a known conceptual failure mode .
Next-step: I can tailor the full protocol logic to your exact constraints
Reply with:
tumor type + PDX line(s) (if known),
whether you edit before engraftment or via in vivo delivery,
which GAS5 KO definition you’ll use (locus KO vs truncation vs functional disruption),
your assay capabilities (RNA-seq? qPCR? histology?),
primary endpoint preference.
Run a Science AI agent to turn this into a fully specified plan (and, if you provide sequences, guide designs + QC checkpoints)
The agent can iteratively produce: a constrained study design decision tree, a validation/QC checklist, and (if you supply GAS5 reference sequence + target definition) guide-level design rationales.
If you provide GAS5 target coordinates (and organism/tumor genome reference), the code will validate target regions, design multiple guides, and produce an edit-validation QC checklist for downstream experimental planning.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A single-guide phenotype driven by delivery stress is unlikely to replicate across multiple independent guides; if discordant guide results appear, the causal interpretation for GAS5 KO should be downgraded (until orthogonal evidence is added).
A phenotype explained solely by clonal drift is plausible if edit-validation shows heterogeneous indels and if engraftment/batch factors differ across groups; this weakens “GAS5 biology” as the primary explanation.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Analysis Wizard
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
